More closely, Wahlstrom et al.15 reported that the administration of the PGI2 analogue epoprostenol significantly decreased C-reactive protein (CRP) and generally decreased IL-6 levels in patients with severe traumatic brain injury compared to placebo. This evidence concerns the gene CRP and brain injury.